Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safet

Drug
egfrm
Indication
Non-small Cell Lung Cancer

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safet — HCM Phase 3 Readout | BioSniper